Prostate Cancer, Sleep, and Cognition

The Impact of Androgen Deprivation Therapy On Sleep And Cognition In Men With Prostate Cancer


This study is examining the effect of androgen deprivation therapy on sleep and cognitive functioning in men with prostate cancer.

This research is important because it will help us to understand how sleep before and during prostate cancer treatment might influence the development of other side effects such as difficulty remembering things and paying attention. This information may be used to help develop targeted prevention and/or intervention programs to help other men in the future.

What Does This Study Involve?

Participation in this study involves completing four assessments of sleep, thinking and memory, urinary symptoms, hot flashes, and emotional wellbeing over the next twelve months at a place of your convenience (pre-treatment, 4, 8, and 12 months). The total time to complete each assessment is estimated to be 40-60 minutes. These assessments can be conducted via telehealth if distance or transportation to St. John's is an issue.

You will also be asked to wear an actigraph and record the details of your sleep for one week following each assessment. An actigraph is a wrist-worn device similar to a watch that can record activity levels throughout the day and night. Recording your sleep details is estimated to take approximately 3 minutes per day. You will be given a stamped, self-addressed envelope to return the sleep diaries and actigraph by mail.

The researcher will assess your verbal learning and memory by asking you to recall lists of words. You will also complete some questionnaires assessing memory, attention, concentration, sleep, fatigue, hot flashes, and mood symptoms.


Primary Investigator:

 Sheila N. Garland, PhD 

(Department of Psychology, Faculty of Science and Division of Oncology, Faculty of Medicine)


John Thoms, MD, FRCPC

 (Division of Oncology, Faculty of Medicine)


Kayla Wall, BSc, 

Samantha Scurrey, BA, 

Nicole Rodriguez, BSc

Supported by grants from the Division of Oncology

at Memorial University and the Beatrice Hunter

Cancer Research Institute (BHCRI)